Torsten O. Nielsen, MD, PhD, FRCPC

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the pros and cons of using the Ki67 as a prognostic marker in breast cancer.

Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, on using a Ki67 assay for patients with breast cancer.